Analytical Data
-
基因名
CTLA-4
-
简介
The CTLA-4 protein is a key inhibitory receptor and a major negative regulator of T cell responses in coordination of immune regulation. Its unique property is its significantly increased affinity for B7 ligands (CD80/CD86) compared with CD28. CTLA-4 Protein, Human (HEK293, mFc) is the recombinant human-derived CTLA-4 protein, expressed by HEK293, with C-mFc labeled tag.
- Application
-
别名
CTLA4; CD152; ICOS; CELIAC3; GRD4; GSE; ALPS5; IDDM12
-
种属
Human
-
表达系统
HEK293
-
标签
C-mFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P16410
-
表达区间
A37-F162
-
分子量
50 kDa,based on SDS-PAGE under reducing conditions,100 kDa,based on SDS-PAGE under non-reduced conditions,due to the glycosylation.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) is an essential immune checkpoint receptor that plays a pivotal role in regulating T-cell activation and maintaining immune homeostasis. It is primarily expressed on activated T-cells and acts as an inhibitory receptor, counteracting the stimulatory signals provided by CD28 and thereby modulating the immune response. Dysregulation of CTLA-4 signaling can lead to autoimmune diseases or contribute to tumor evasion from immune surveillance, making it a significant target in cancer immunotherapy. The development of CTLA-4 recombinant proteins or monoclonal antibodies, such as ipilimumab, has demonstrated substantial clinical efficacy in enhancing anti-tumor immune responses. These therapies work by blocking CTLA-4 interactions, thereby augmenting T-cell activation and proliferation against cancer cells. Given the complexity of the immune system and the role of CTLA-4 in various diseases, ongoing research focuses on elucidating the molecular mechanisms of CTLA-4, optimizing therapeutic strategies, and exploring combinations with other immune checkpoint inhibitors to improve clinical outcomes for patients with malignancies and chronic infections. The increased understanding of CTLA-4 biology provides a foundation for innovative therapeutic approaches that harness the immune system more effectively in combating cancer and other immune-related disorders.
